RU2645071C2 - Способы гликоконъюгирования и композиции - Google Patents

Способы гликоконъюгирования и композиции Download PDF

Info

Publication number
RU2645071C2
RU2645071C2 RU2015103017A RU2015103017A RU2645071C2 RU 2645071 C2 RU2645071 C2 RU 2645071C2 RU 2015103017 A RU2015103017 A RU 2015103017A RU 2015103017 A RU2015103017 A RU 2015103017A RU 2645071 C2 RU2645071 C2 RU 2645071C2
Authority
RU
Russia
Prior art keywords
saccharide
capsular polysaccharide
kda
polysaccharide
carrier protein
Prior art date
Application number
RU2015103017A
Other languages
English (en)
Russian (ru)
Other versions
RU2015103017A (ru
Inventor
Цзяньсинь ГУ
Чжин-хван КИМ
А. Кришна Прасад
Ю-Йин ЯНГ
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of RU2015103017A publication Critical patent/RU2015103017A/ru
Application granted granted Critical
Publication of RU2645071C2 publication Critical patent/RU2645071C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
RU2015103017A 2012-08-16 2013-08-12 Способы гликоконъюгирования и композиции RU2645071C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261684043P 2012-08-16 2012-08-16
US61/684,043 2012-08-16
PCT/IB2013/056597 WO2014027302A1 (en) 2012-08-16 2013-08-12 Glycoconjugation processes and compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2016136630A Division RU2724840C2 (ru) 2012-08-16 2013-08-12 Способы гликоконъюгирования и композиции

Publications (2)

Publication Number Publication Date
RU2015103017A RU2015103017A (ru) 2016-10-10
RU2645071C2 true RU2645071C2 (ru) 2018-02-15

Family

ID=49385307

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016136630A RU2724840C2 (ru) 2012-08-16 2013-08-12 Способы гликоконъюгирования и композиции
RU2015103017A RU2645071C2 (ru) 2012-08-16 2013-08-12 Способы гликоконъюгирования и композиции

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2016136630A RU2724840C2 (ru) 2012-08-16 2013-08-12 Способы гликоконъюгирования и композиции

Country Status (32)

Country Link
US (6) US9517274B2 (OSRAM)
EP (2) EP3421051B1 (OSRAM)
JP (1) JP6291495B2 (OSRAM)
KR (1) KR101742406B1 (OSRAM)
CN (1) CN104661684B (OSRAM)
AR (1) AR092368A1 (OSRAM)
AU (1) AU2013303826B2 (OSRAM)
BR (1) BR112015003227B1 (OSRAM)
CA (1) CA2881420C (OSRAM)
DK (2) DK2885007T3 (OSRAM)
ES (2) ES2700824T3 (OSRAM)
FI (1) FIC20220032I1 (OSRAM)
FR (1) FR22C1037I2 (OSRAM)
HU (3) HUE049531T2 (OSRAM)
IL (1) IL237066B (OSRAM)
IN (1) IN2015DN00694A (OSRAM)
LU (1) LUC00273I2 (OSRAM)
MX (1) MX363511B (OSRAM)
MY (1) MY167579A (OSRAM)
NL (1) NL301188I2 (OSRAM)
NO (1) NO2022034I1 (OSRAM)
NZ (1) NZ704490A (OSRAM)
PE (1) PE20150464A1 (OSRAM)
PH (1) PH12015500243B1 (OSRAM)
PL (2) PL2885007T3 (OSRAM)
PT (2) PT2885007T (OSRAM)
RU (2) RU2724840C2 (OSRAM)
SA (1) SA515360035B1 (OSRAM)
SG (1) SG11201500566XA (OSRAM)
SI (2) SI3421051T1 (OSRAM)
TW (1) TWI480049B (OSRAM)
WO (1) WO2014027302A1 (OSRAM)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3421051B1 (en) 2012-08-16 2020-05-13 Pfizer Inc Glycoconjugation processes and compositions
HRP20211288T1 (hr) * 2014-01-21 2021-11-26 Pfizer Inc. Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati
EP3096785B1 (en) 2014-01-21 2020-09-09 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PT3096783T (pt) * 2014-01-21 2021-08-16 Pfizer Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos
EP3443983B1 (en) 2014-02-14 2022-07-20 Pfizer Inc. Immunogenic glycoprotein conjugates
RU2760005C2 (ru) 2014-03-13 2021-11-22 Университет Базель УГЛЕВОДНЫЕ ЛИГАНДЫ, КОТОРЫЕ СВЯЗЫВАЮТСЯ С IgM АНТИТЕЛАМИ ПРОТИВ МИЕЛИН-АССОЦИИРОВАННОГО ГЛИКОПРОТЕИНА
CN107427568B (zh) 2015-01-15 2021-12-14 辉瑞公司 用于肺炎球菌疫苗中的免疫原性组合物
RU2692923C2 (ru) * 2015-05-04 2019-06-28 Пфайзер Инк. Конъюгаты полисахарида стрептококка группы В и белка, способы получения конъюгатов, иммуногенные композиции, содержащие конъюгаты, и их применения
CA2988366C (en) * 2015-06-08 2021-12-07 Serum Institute Of India Private Ltd. Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof.
IL303998A (en) 2015-07-21 2023-08-01 Pfizer Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses
AU2016323377B2 (en) 2015-09-16 2021-04-15 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
CA3031799A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
MY199342A (en) 2016-08-05 2023-10-24 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
RS65362B1 (sr) 2016-09-02 2024-04-30 Sanofi Pasteur Inc Vakcina protiv neisseria meningitidis
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
MX2019007910A (es) 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.
WO2018134693A1 (en) 2017-01-20 2018-07-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
MX2019014829A (es) * 2017-06-10 2020-08-17 Inventprise Llc Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
AU2018328040B2 (en) * 2017-09-07 2025-01-16 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
US11491216B2 (en) 2017-09-07 2022-11-08 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
KR102812816B1 (ko) 2018-02-05 2025-05-27 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
JP6950099B2 (ja) 2018-02-05 2021-10-13 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体−タンパク質複合体組成物
KR20200141053A (ko) * 2018-03-23 2020-12-17 코라넥스 캐피탈 치료 도구로서의 정밀 당 접합체
BR112020021296A2 (pt) 2018-04-18 2021-01-26 Sk Bioscience Co., Ltd. polissacarídeo capsular de streptococcus pneumoniae e conjugado imunogênico do mesmo
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN111024832B (zh) * 2019-10-29 2022-05-03 北京成大天和生物科技有限公司 多糖结合疫苗中残余NaCNBH3的离子色谱检测方法
MX2022005252A (es) 2019-11-01 2022-06-08 Pfizer Composiciones de escherichia coli y metodos de las mismas.
JP2021132644A (ja) 2020-02-21 2021-09-13 ファイザー・インク 糖の精製
IL295632A (en) 2020-02-23 2022-10-01 Pfizer Escherichia coli preparations and their methods
WO2022035816A1 (en) 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
BR112023004819A2 (pt) 2020-09-17 2023-04-18 Janssen Pharmaceuticals Inc Composições de vacinas multivalentes e seus usos
WO2022084852A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
EP4237428A2 (en) 2020-10-27 2023-09-06 Pfizer Inc. Escherichia coli compositions and methods thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US20240000912A1 (en) 2020-11-04 2024-01-04 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
CA3221074A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2024521847A (ja) 2021-05-28 2024-06-04 ファイザー・インク コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
PE20251701A1 (es) 2022-11-22 2025-07-02 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
KR20250113501A (ko) 2022-12-01 2025-07-25 화이자 인코포레이티드 폐렴구균 접합체 백신 제형
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024255922A1 (en) 2023-04-14 2025-10-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007071707A2 (en) * 2005-12-22 2007-06-28 Glaxosmithkline Biologicals Sa Pneumococcal polysaccharide conjugate vaccine
WO2007141077A1 (de) * 2006-06-07 2007-12-13 Continental Aktiengesellschaft Verfahren und messfahrzeug zur ermittlung objektiver reifeneigenschaften auf einer fahrbahnoberfläche
WO2008157590A1 (en) * 2007-06-20 2008-12-24 Baxter International Inc. Modified polysaccharides for conjugate vaccines
RU2378015C2 (ru) * 2008-04-02 2010-01-10 Равшан Иноятович Атауллаханов Конъюгат для иммунизации и вакцинации и способ повышения иммуногенности

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US578573A (en) 1897-03-09 Brake-actuating mechanism
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
EP0616034B1 (en) 1993-03-05 2004-10-20 Wyeth Holdings Corporation Plasmid for production of CRM protein and diphtheria toxin
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
WO1998056942A1 (en) 1997-06-12 1998-12-17 Shin-Etsu Bio, Inc. Production of non-native bacterial exopolysaccharide in a recombinant bacterial host
MXPA01003228A (es) 1998-09-30 2003-06-24 American Cyanamid Co Holotoxina de colera mutante como un coadyuvante.
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
YU66103A (sh) * 2001-01-23 2006-05-25 Aventis Pasteur Vakcina multivalentnog konjugata meningokokalnog polisaharid-proteina
DE60234695D1 (de) 2001-06-07 2010-01-21 Univ Colorado Mutantenformen von cholera holotoxin als adjuvans
AU2002322380B2 (en) 2001-06-07 2006-11-02 Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutant forms of cholera holotoxin as an adjuvant
CN1394867A (zh) * 2001-07-06 2003-02-05 中国科学院生态环境研究中心 可作药物的寡糖和其制备方法及含该寡糖的药物组合物
WO2004031394A2 (en) * 2002-10-03 2004-04-15 Wyeth Holdings Corporation Process for preparing monoprotected diols from symmetric diols
JP5102487B2 (ja) * 2003-03-07 2012-12-19 ワイス・ホールディングズ・コーポレイション 院内感染に対する免疫化のための多糖ブドウ球菌表面付着因子キャリアタンパク質接合体
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
JP2007532655A (ja) * 2004-04-14 2007-11-15 ワイス ラパマイシンコンジュゲートおよび抗体のための前駆体である、ジカルボン酸とのラパマイシン４２−エステルおよびジカルボン酸とのｆｋ−５０６３２−エステルの調製プロセス
US7910753B2 (en) * 2004-09-10 2011-03-22 Anaspec Incorporated Cyanine dyes and their applications as luminescence quenching compounds
EP2425856A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
TW200806685A (en) * 2006-02-21 2008-02-01 Wyeth Corp Processes for the convergent synthesis of calicheamicin derivatives
US7605257B2 (en) * 2006-03-07 2009-10-20 Wyeth Processes for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants
US20070253985A1 (en) 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
JP5837486B2 (ja) * 2009-07-03 2015-12-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル カチオン非依存性マンノース６−リン酸受容体を標的とする化合物
PL2503995T3 (pl) * 2009-11-24 2018-01-31 Grifols Therapeutics Inc Sposoby liofilizacji, kompozycje i zestawy
RU2013131795A (ru) * 2010-12-10 2015-01-20 Мерк Шарп Энд Домэ Корп. Новые композиции, которые уменьшают вызываемую встряхиванием агрегацию иммуногенных композиций
MX358840B (es) * 2011-09-07 2018-09-05 Prolynx Llc Hidrogeles con reticulación biodegradable.
EP3421051B1 (en) 2012-08-16 2020-05-13 Pfizer Inc Glycoconjugation processes and compositions
EP3096785B1 (en) 2014-01-21 2020-09-09 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3443983B1 (en) 2014-02-14 2022-07-20 Pfizer Inc. Immunogenic glycoprotein conjugates

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007071707A2 (en) * 2005-12-22 2007-06-28 Glaxosmithkline Biologicals Sa Pneumococcal polysaccharide conjugate vaccine
US20090017059A1 (en) * 2005-12-22 2009-01-15 Glaxosmithkline Biologicals S.A. Vaccine Comprising Streptococcus Pneumoniae Capsular Polysaccharide Conjugates
WO2007141077A1 (de) * 2006-06-07 2007-12-13 Continental Aktiengesellschaft Verfahren und messfahrzeug zur ermittlung objektiver reifeneigenschaften auf einer fahrbahnoberfläche
WO2008157590A1 (en) * 2007-06-20 2008-12-24 Baxter International Inc. Modified polysaccharides for conjugate vaccines
RU2378015C2 (ru) * 2008-04-02 2010-01-10 Равшан Иноятович Атауллаханов Конъюгат для иммунизации и вакцинации и способ повышения иммуногенности

Also Published As

Publication number Publication date
NL301188I2 (nl) 2024-05-15
PE20150464A1 (es) 2015-04-25
HUE041381T2 (hu) 2019-05-28
CA2881420C (en) 2016-11-15
SI2885007T1 (sl) 2018-12-31
US20170224804A1 (en) 2017-08-10
FIC20220032I1 (fi) 2022-08-05
DK2885007T3 (en) 2018-12-03
US20230355735A1 (en) 2023-11-09
RU2724840C2 (ru) 2020-06-25
ES2700824T3 (es) 2019-02-19
FR22C1037I1 (fr) 2022-09-09
PH12015500243B1 (en) 2019-05-31
RU2016136630A3 (OSRAM) 2019-12-30
KR20150041139A (ko) 2015-04-15
EP3421051A1 (en) 2019-01-02
RU2016136630A (ru) 2018-12-11
NO2022034I1 (no) 2022-08-04
JP6291495B2 (ja) 2018-03-14
EP2885007A1 (en) 2015-06-24
ES2800479T3 (es) 2020-12-30
PT3421051T (pt) 2020-06-26
US11110160B2 (en) 2021-09-07
JP2015524839A (ja) 2015-08-27
FR22C1037I2 (fr) 2023-05-26
BR112015003227B1 (pt) 2020-10-27
US10583187B2 (en) 2020-03-10
US20200246448A1 (en) 2020-08-06
PH12015500243A1 (en) 2015-03-30
AU2013303826A1 (en) 2015-02-12
US12447203B2 (en) 2025-10-21
MY167579A (en) 2018-09-20
MX363511B (es) 2019-03-26
HUS2200034I1 (hu) 2022-08-28
KR101742406B1 (ko) 2017-05-31
CN104661684A (zh) 2015-05-27
TWI480049B (zh) 2015-04-11
LUC00273I2 (OSRAM) 2025-05-12
CN104661684B (zh) 2018-03-20
US9950054B2 (en) 2018-04-24
SG11201500566XA (en) 2015-04-29
PT2885007T (pt) 2018-12-10
MX2015001992A (es) 2015-10-05
US11723965B2 (en) 2023-08-15
IN2015DN00694A (OSRAM) 2015-06-26
SI3421051T1 (sl) 2020-08-31
SA515360035B1 (ar) 2015-09-15
AR092368A1 (es) 2015-04-15
US20150216996A1 (en) 2015-08-06
IL237066B (en) 2019-03-31
US20220096619A1 (en) 2022-03-31
US9517274B2 (en) 2016-12-13
EP2885007B1 (en) 2018-10-10
TW201420115A (zh) 2014-06-01
HK1210021A1 (en) 2016-04-15
NZ704490A (en) 2017-07-28
US20180221467A1 (en) 2018-08-09
DK3421051T3 (da) 2020-06-22
EP3421051B1 (en) 2020-05-13
AU2013303826B2 (en) 2017-06-29
HUE049531T2 (hu) 2020-10-28
RU2015103017A (ru) 2016-10-10
CA2881420A1 (en) 2014-02-20
WO2014027302A1 (en) 2014-02-20
PL2885007T3 (pl) 2019-02-28
PL3421051T3 (pl) 2020-10-05
BR112015003227A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
US12447203B2 (en) Glycoconjugation processes and compositions
US20240033367A1 (en) Immunogenic glycoprotein conjugates
HK1210021B (en) Glycoconjugation processes and compositions